Brief: Mineralys Therapeutics Says Positive Lorundrostat Results From The Phase 2 Target-Htn Trial At ACC.23/Wcc
04/03/2023 21:32
March 4 (Reuters) - Mineralys Therapeutics Inc MLYS.O :
* MINERALYS THERAPEUTICS PRESENTS POSITIVE LORUNDROSTAT
RESULTS
FROM THE PHASE 2 TARGET-HTN TRIAL AT ACC.23/WCC
* LORUNDROSTAT DEMONSTRATED CLINICALLY MEANINGFUL BLOOD
PRESSURE
REDUCTION IN INDIVIDUALS WITH UNCONTROLLED HYPERTENSION
* MINERALYS THERAPEUTICS - OBESITY WAS PREDICTIVE OF
ENHANCED
RESPONSE TO LORUNDROSTAT WITH PLACEBO-ADJUSTED SYSTOLIC BP
REDUCTION OF 16.7 MMHG WITH 50MG ONCE-DAILY DOSING
* ADDITIONAL CLINICAL TRIAL EXPECTED TO BEGIN IN FIRST HALF
OF
2023
Source text for Eikon: ID:nGNX4C9B7Y
Further company coverage: MLYS.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Mineralys Therapeutics
See all newsBrief: Mineralys Therapeutics Expands Its Board Of Directors With The Appointments Of Kristine Peterson And Lonnel Coats
Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway